Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease (Q46484079)

22 December 2017

title

Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease (English)

1 reference

22 December 2017

enzyme replacement therapy

main subject

0 references

1 reference

1 reference

7

Yuan-Tsong Chen

1 reference

22 December 2017

author name string

Yan An

1

1 reference

22 December 2017

Sarah P Young

2

1 reference

22 December 2017

Priya S Kishnani

3

1 reference

22 December 2017

David S Millington

4

1 reference

22 December 2017

Andrea Amalfitano

5

1 reference

22 December 2017

Deyanira Corz

6

1 reference

22 December 2017

publication date

1 August 2005

1 reference

22 December 2017

Molecular Genetics and Metabolism

published in

1 reference

22 December 2017

volume

85

1 reference

22 December 2017

page(s)

247-254

1 reference

22 December 2017

issue

4

1 reference

22 December 2017

Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Recombinant human acid alpha-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Recombinant human alpha-glucosidase from rabbit milk in Pompe patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Multiple muscles in the AMD quail can be “cross‐corrected” of pathologic glycogen accumulation after intravenous injection of an [E1‐, polymerase‐] adenovirus vector encoding human acid‐α‐glucosidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Increased urinary excretion of a glycogen-derived tetrasaccharide in heterozygotes with glycogen storage diseases type II and III

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution–electrospray ionization tandem mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Analysis of sialyllactoses in blood and urine by high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Urinary excretion of a glucose-containing tetrasaccharide. A parameter for increased degradation of glycogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Enzyme-replacement therapy in mucopolysaccharidosis I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Monitoring dose response of enzyme replacement therapy in feline mucopolysaccharidosis type VI by tandem mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.010

10.1016/J.YMGME.2005.03.010

7 January 2021

Identifiers

DOI

1 reference

22 December 2017

PubMed ID

15886040

1 reference

22 December 2017